61 results about "Metalloproteinase" patented technology

The invention discloses application of tea extracellular vesicles in preparation of a product for preventing and / or treating UVB-induced skin photoaging, and belongs to the technical field of application of the tea extracellular vesicles. The tea extracellular vesicles are derived from tea leaves and / or stem leaves and are prepared by a method of combining enzymolysis, multi-stage filtration and ultracentrifugation, and the particle size of the tea extracellular vesicles is mainly distributed in a range of 60-100nm. Experiments show that the tea extracellular vesicles can effectively reduce active oxygen accumulation and lipid peroxidation caused by UVB radiation, repair mitochondrial membrane potential and inhibit expression of matrix metalloproteinase and inflammatory factors, so that photoaging symptoms such as skin wrinkles, erythema and barrier function damage are relieved. The tea extracellular vesicle provided by the invention has the advantages of natural raw materials, good biocompatibility, small side effect and the like, can be used for preparing a plurality of external dosage forms such as gel, cream, spray and the like, and provides a safe and effective new natural product choice for prevention and treatment of skin photoaging.

A water-soluble unit dose detergent article including a water-soluble film and a laundry liquid detergent composition, wherein the detergent composition includes:a non-soap surfactant system including anionic non-soap surfactant and nonionic surfactant wherein the anionic non-soap surfactant includes more than 0% and less than 20% by weight of the anionic non-soap surfactant of an anionic non-soap surfactant selected from the group consisting of alkyl sulphate, alkoxylated alkyl sulphate, and a mixture thereof;a metalloprotease; andup to 15% by weight of the composition of water.

The invention provides responsive release polypeptide hydrogel. The hydrogel comprises a gel product of a raw material composition containing the following raw material components: (A) a biocompatible polymer containing at least two sulfydryl groups; (B) a matrix metalloproteinase substrate polypeptide; (C) a compound containing a phenolic hydroxyl group structure; (D) a cross-linking agent; and (E) water; the sequence of the matrix metalloproteinase substrate polypeptide is at least one of the following sequences (b1) to (b2): (b1) Cys-Pro-Leu-Gly-Val-Arg-Gly-Arg-Gly-Asp-Ser, (b2) Cys-Pro-Leu-Gly-Val-Arg-Gly-Asp-Ser, (b3) Cys-Pro-Leu-Gly-Val-Arg-Gly (b2), Dnp-Pro-Leu-Gly-Met-Trp-Ser-Arg-C-ys, and (b3), Dnp-Pro-Leu-Gly- The responsive release polypeptide hydrogel can release polypeptide in a cell microenvironment to promote tissue regeneration and repair, and can be used for preparing muscle-bone healing promoting materials and treating ligament injury diseases such as rotator cuff injury.

A composition is provided comprising a cell population and pharmaceuticals derived from human gingival fibroblasts, present in proportions not found in natural gingival tissue, but having a cellular phenotype preferentially selected to express proteins favorable for angiogenesis and anti-inflammatory effects, while reducing the formation of cell populations that promote tumorigenesis and / or metalloproteinases that inhibit tissue regeneration. A method for producing such a composition that increases proliferation several times over compared to previously known methods is provided, and a method for using such a composition in a wide range of human cell therapies is also provided.

The present invention relates to a method for modifying meat, including bringing the meat in contact with a Bacillus amyloliquefaciens-derived neutral protease having the following properties (a) to (e), and thermolysin; (a) being an enzyme that hydrolyzes a substrate having a peptide bond to release the peptide, (b) having an optimal pH of 7, (c) being stable at pH=5 to 7, (d) having an optimal temperature of 50°C to 55°C, (e) being a metal protease inhibited by ethylenediaminetetraacetic acid (EDTA), and a composition for modification, containing said neutral protease and thermolysin. According to the present invention, meat can be tenderized conveniently in a short time, and ease of loosening can be imparted to the meat.

The present invention relates to a composition for protecting cells from endoplasmic reticulum (ER) stress and oxidative stress induced by ultrafine dust, comprising galangin as an active ingredient. Galangin, which is an active ingredient of the composition for cell protection of the present invention, alleviated an increase in reactive oxygen species, intracellular calcium, and ER stress-related proteins induced by ultrafine dust PM2.5. In addition, galangin counteracted PM2.5-induced cell cycle arrest at the G0 / G1 phase and restored cell cycle regulators and matrix metalloproteinases. As a result, galangin can enhance cell protection against PM2.5-induced ER stress and cell cycle arrest via reactive oxygen species. Therefore, it is suggested that the composition comprising galangin as an active ingredient of the present invention has great potential as a candidate for a preventive agent or a therapeutic agent for diseases related to ER stress and oxidative stress induced by PM2.5.

The invention provides a biomarker composition and an application thereof. The biomarker composition comprises the following proteins: MMP12, UMOD, HbA1c, FGF9, NINJ1 and PRSS8. According to the biomarker composition provided by the invention, through combination of matrix metalloproteinase 12, uromodulin, glycosylated hemoglobin, FGF9, NINJ1 and serine protease 8, the problem of lack of a specific marker for aortic wall structure damage in the prior art is solved.

The application provides an engineered exosome loaded with a CD63 transmembrane domain-matrix metalloproteinase fusion protein and a preparation method and application thereof. The engineered exosome is secreted by a genetically engineered mesenchymal stem cell, has a CD63 derived transmembrane domain anchored on the membrane, and has a matrix metalloproteinase (MMP) loaded on the inner side of the membrane. The fusion protein comprises, from N-terminus to C-terminus, a fourth transmembrane domain and a C-terminal cytoplasmic tail of a human CD63 protein, a flexible linker peptide, and a human MMP without a natural signal peptide. The application realizes efficient and directional loading of MMPs by using a natural biological generation path of the exosome, shields the inhibition of MMPs by metalloproteinase tissue inhibitors in a scar tissue by using the membrane of the exosome, realizes specific activation of MMPs in a target cell, degrades abnormally deposited collagen, adjusts the ratio of type I and type III collagens, and plays an anti-fibrosis and anti-scar formation role. The application also provides a preparation method of the engineered exosome and application thereof in preparation of a medicine for preventing or treating pathological scars.

This invention discloses carboxymethyl sucrose amino acid salts, their preparation, compositions, and applications. The salts are prepared from carboxymethyl sucrose and arginine, or carboxymethyl sucrose and glycine, through a chemical reaction. The resulting salts undergo a series of processes including primary alcohol precipitation, redissolution, secondary alcohol precipitation, redissolution, tertiary alcohol precipitation, soaking, pulverization, filtration, and drying to obtain carboxymethyl sucrose arginine and carboxymethyl sucrose glycine salts. A composition is prepared by mixing these two salts. Both salts and the composition significantly inhibit the activity of matrix metalloproteinase 1 and promote the expression of type I collagen, thus delaying aging by maintaining the stability of collagen morphology and structure in the extracellular matrix. The preparation method of this invention is simple and the process conditions are mild. The product has the advantages of being weakly acidic, gentle on the skin, highly safe, and having good anti-aging effects. It can be widely used in skin care cosmetics and has promising application prospects.

The application discloses application of dihydroxy isobutyryl modification of a GIT1-K131 site in treatment of VSMC injury or aortic dissection; in the application, 2-HIBA specifically up-regulates the Khib modification level of the K131 site of the GIT1 protein by targeting inhibition of expression of HDAC1, thereby effectively inhibiting conversion of VSMC from a contraction phenotype to a synthesis phenotype, reducing expression of matrix metalloproteinase, reducing apoptosis, restoring normal functions of VSMC, and finally significantly relieving key pathological characteristics of AD such as aortic dilation, elastic fiber degradation and collagen deposition, so that occurrence and progression of AD are effectively delayed.

The invention discloses application of cyclic peptide or salt thereof in cosmetics, and belongs to the technical field of cosmetic peptides, the natural cyclic peptide comprises alanine (Ala), glycine (Gly), proline (Pro), valine (Val) and tyrosine (Tyr), and is a compound with the following formula I. The invention further discloses a preparation method of the natural cyclic peptide. The cyclopeptide compound disclosed by the invention has the effects of promoting generation of type I collagen and elastin, inhibiting generation of matrix metalloproteinase I (MMP-1) under UVA irradiation and preventing collagen degradation, so that the cyclopeptide compound has the effects of resisting wrinkles, tightening skin and the like.

The invention discloses a serum protein marker combination for detecting cerebral microhemorrhage, and belongs to the field of biological medicine detection.The serum protein marker combination comprises four serum proteins including matrix metalloproteinase 3, fibronectin-like extracellular matrix protein 1 containing epidermal growth factors, a metalloproteinase inhibiting factor 1 and uromodulin; through efficient and accurate serum protein marker combination, the defects that brain function magnetic resonance SWI examination is high in cost and long in time consumption, operation depends on high-level imaging physicians and the like are overcome, an innovative tool is provided for rapid, accurate and non-invasive screening and auxiliary diagnosis of cerebral microhemorrhage, and wide clinical application prospects are achieved.

Methods of decreasing shedding of CD28, decreasing soluble CD28 levels, treating cancer and improving immunotherapies comprising inhibiting matrix metalloproteases are provided. Methods of producing agents for performance of the methods of the invention are also provided.

The invention discloses a preparation method and application of a PSA-ACT compound recombinant protein. The preparation method comprises the following steps: obtaining gene segments of recombinant PSA and ACT proteins; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation, transfection, induction and fermentation broth separation and purification operation on the recombinant plasmid to obtain recombinant PSA and ACT proteins; then activating PSA recombinant protein by using metalloproteinase, and then mixing ACT with the activated PSA to obtain a mixture containing the PSA, ACT and a PSA-ACT compound; and finally, purifying by using an ion exchange chromatography technology and a hydrophobic chromatography technology in sequence to obtain the high-purity and high-activity PSA-ACT compound. According to the method, the spontaneous reaction of ACT and activated PSA is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, and the recombinant protein can be produced on a large scale; the PSA-ACT recombinant protein prepared by the method disclosed by the invention has very strong immunoreactivity.

The invention discloses porphyra yezoensis polysaccharide PSP-I with anti-ultraviolet damage activity as well as a preparation method and application of the porphyra yezoensis polysaccharide PSP-I. The Mw of the PSP-I is 26.149 kDa, the Mn of the PSP-I is 11.267 kDa, and the molar ratio of galactose to glucose to glucuronic acid in monosaccharide composition of the PSP-I is 96.76: 2.31: 0.93. The preparation method comprises the following steps: pretreating a nori raw material, extracting crude polysaccharide by adopting an enzyme method, deproteinizing, dialyzing, collecting a main polysaccharide elution peak by utilizing anion exchange chromatography, further purifying by virtue of sephadex chromatography, collecting the main elution peak, removing impurities and drying, thereby obtaining the nori polysaccharide. The polysaccharide PSP-I can effectively remove active oxygen induced by UVB, inhibit apoptosis and down-regulate expression of matrix metalloproteinase in cells under a safe concentration, shows excellent anti-light aging activity, and can be used for preparing cosmetics or skin care products for resisting ultraviolet damage.

The application belongs to the technical field of biotechnology and cosmetics, and discloses a polypeptide with skin barrier repair activity and application thereof. The polypeptide is an enzymatic fragment derived from Bacillus subtilis neutral metalloproteinase A7UAM1, and the amino acid sequence is shown as SEQ ID NO:1. The mutant is a site-directed mutant of the wild-type A7UAM1, and is preferably a H142A / E143A double mutant. Compared with the wild-type enzyme, the proteolytic activity of the polypeptide and the mutant is reduced by greater than or equal to 90%, but the activity of promoting keratinocytes to express filaggrin (FLG) and loricrin (LOR) is not reduced or is significantly improved, and the application realizes the decoupling of the functions of 'gentle exfoliation' and 'active barrier repair'. The polypeptide or the mutant can be applied to the preparation of cosmetics or drugs with the effects of skin barrier repair, anti-sensitivity and anti-photoaging, and is especially suitable for sensitive skin and post-medical aesthetic repair.

The present invention provides a biomarker for the detection of glioma microenvironment (TME), comprising a serum marker selected from any one or more of annexin A1 (ANXA1), annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2), and a pathological marker selected from any one or more of Annexin A1 (ANXA1), Annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2); the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and a phospholipase A2 group IIA (PLA2G2A), and the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and phospholipase A2 group IIA (PLA2G2A). The invention also provides an application of the biomarker in diagnosis of glioma. The invention provides an innovative idea and a biomarker for non-invasive diagnosis of glioma, and can be used for prognosis and malignant diagnosis of glioma.

The invention discloses an online cleaning method for cation exchange filler. The cleaning method is used for cleaning the cation exchange filler after metalloproteinase is purified. The cleaning method comprises the following steps: respectively using an acid solution, a chelating agent solution, a salt solution, an alkali solution and water as cleaning agents, and sequentially cleaning the cation exchange filler. The online cleaning method for the cation exchange filler is used for cleaning the cation exchange filler after metalloproteinase is purified, metal ion pollutants and other pollutants in the cation exchange filler can be effectively removed, the protein loading capacity of the cation exchange filler can be recovered, the service life of the cation exchange filler can be prolonged, and the service life of the cation exchange filler can be prolonged. And the use cost of the cation exchange filler is reduced.

The present invention relates to novel hydroxamic acid derivatives useful as inhibitors of astacin metalloproteinases, in particular procollagen C-proteinase (PCP) enzymes, meprins, ovastacin and / or nematode astacins; more particularly human or mammalian meprin α, meprin β, BMP-1, ovastacin and / or DPY-31 from nematodes; pharmaceutical compositions comprising such compounds; methods for treatment or prophylaxis of diseases or conditions, especially such that are related to said metalloproteinases; and compounds and pharmaceutical compositions for use in such methods

The invention relates to the technical field of medical data processing, and discloses a periodontitis risk screening system based on family history and saliva inflammation marker detection, which comprises a data acquisition front end, a physical detection suite and a background risk calculation engine. The data acquisition front end acquires the medical history and smoking history of relatives, quantifies the medical history and smoking history into genetic and environmental factor scores, and captures a detection image containing test paper and a standard colorimetric card at the same time. The physical detection kit comprises saliva matrix metalloproteinase-8 test paper and a colorimetric card for providing a white balance reference. The background engine performs white balance correction and analysis on the image by using the colorimetric card data to obtain a biomarker score; and performing normalization and weighted fusion calculation on genetic, environmental and biomarker scores to generate a comprehensive risk total score and a risk grade. Through the image correction and data fusion technology, the ambient light interference is eliminated, and the comprehensive quantitative evaluation of the genetic background and the current pathological state is realized.

The present patent application discloses a kind of recombinant collagen VII and its preparation method and use.The recombinant collagen VII is obtained by multiple repetitions of short amino acid sequence GLPGAKGEKGAP.The secretory yield of the recombinant collagen VII in commercialized pichia expression system can be as high as about 17.3g / L, the extracellular secreted protein is basically not degraded during fermentation process, and more than 90% purity can be achieved by simple ultrafiltration and decolorization, industrial production can be realized;Moreover, the recombinant collagen VII has more optimal biological activities of promoting autophagy, improving endoplasmic reticulum stress state, promoting collagen secretion and inhibiting matrix metalloproteinase degradation of collagen, and shows good firming and anti-wrinkle effects.

It suppresses the expression of matrix metalloproteinase 1. [Solution] The disclosed matrix metalloproteinase 1 expression inhibitor contains as an active ingredient at least one selected from the group consisting of Saxifraga stolonifera, Saxifraga stolonifera extract, Rosemary, Rosemary extract, Licorice, Licorice extract, Melissa, Melissa extract, Wild thyme, Wild thyme extract, Hops, and Hops extract.

The application discloses a semi-chemical synthesis method of an N-terminal domain of matrix metalloproteinase inhibitor-2 (N-TIMP2) and application thereof. The N-TIMP2 is divided into three fragments, wherein a key tyrosine post-translational modification site is located in the fragment 2; the polypeptide resins of the fragment 1 and the fragment 2 are synthesized by using a solid-phase polypeptide synthesis technology, and the fragment 1 and the fragment 2 with a C-terminal hydrazide are obtained after cleavage, deprotection, extraction and purification; the fragment 3 is obtained by combining an E. coli recombinant expression technology and a three-step one-pot selective protection reaction of side chains of mercapto; the fragment 1, 2 connecting product is obtained through a first-step natural chemical connecting reaction; the full-length linear protein is obtained through a second-step natural chemical connecting reaction, desulfurization and deprotection; and finally, the N-TIMP2 protein is obtained through a refolding reaction. The semi-chemically synthesized N-TIMP2 protein has a comparable MMP-14 inhibiting activity to the N-TIMP2 protein obtained by using the E. coli recombinant expression technology.

This invention relates to the pharmaceutical field, specifically to the application of tissue inhibitor metalloproteinases-2 (TIMP2) in the preparation of drugs for the prevention or treatment of traumatic brain injury. TIMP2 protein can increase the fall latency in rotarod experiments in mice with traumatic brain injury; improve the motor balance ability of mice with traumatic brain injury on a balance beam; improve neurological function impairment in mice with traumatic brain injury; and reduce Evans blue permeability in brain tissue. In brain microvascular endothelial cells (HBMECs), TIMP2 protein can participate in maintaining the integrity of the endothelial barrier, reversing the loss of expression and altered localization of the connectome complex induced in an in vitro traumatic brain injury model, and reducing luciferase leakage. This invention also provides the application of TIMP2 protein as an Integrin α3β1 ligand in the preparation of drugs for the treatment of central nervous system diseases caused by blood-brain barrier dysfunction. TIMP2 protein exerts its function by binding to the cell membrane receptor Integrin α3β1, regulating VE-Cadherin phosphorylation. TIMP2 protein shows promising application prospects in the treatment of blood-brain barrier dysfunction caused by traumatic brain injury.

The invention belongs to the technical field of cosmetics, and discloses a dual synergistic anti-aging and anti-inflammatory composition and application thereof. The composition disclosed by the invention is prepared from benzylidene dimethoxy dimethyl indanone and a radix pseudostellariae extract, the mass ratio of the benzylidene dimethoxy dimethyl indanone to the radix pseudostellariae extract is (1: 0.01) to (1: 500000). By combining the benzylidene dimethoxy dimethyl indanone and the radix pseudostellariae extract, extracellular matrix and senescent cell related secretion phenotypes can be effectively improved, cell damage and senescence caused by UVA and UVB can be improved, expression of collagen and elastin can be promoted, expression of matrix metalloproteinase can be inhibited, expression of proinflammatory factors can be inhibited, and the anti-aging effect can be achieved. And the compound shows good anti-aging and anti-inflammatory effects at a relatively low concentration.

The present disclosure discloses a composition for skin anti-aging, skin lightening, or skin texture improvement containing a metalloproteinase derived from a strain of the genus Chryseobacterium as an active ingredient, and / or a composition for inhibition of lipofuscin accumulation or for removal of lipofuscin containing the metalloproteinase as an active ingredient. The composition provides an efficacy of skin anti-aging, skin lightening, or skin texture improvement by inhibition of lipofuscin accumulation or by removal of lipofuscin, and provides an effect of preventing, improving, or treating a disease caused by lipofuscin accumulation.

Disclosed in the present disclosure is a composition for skin aging resistance, skin whitening, or skin quality improvement containing, as an active ingredient, a metalloprotease derived from a strain of the genus Chryseobacterium, and / or a composition for inhibiting lipofuscin deposition or eliminating lipofuscin containing, as an active ingredient, the metalloprotease. The composition provides skin anti-aging, skin whitening or skin quality improving efficacy by inhibiting lipofuscin deposition or removing lipofuscin, and provides an effect of preventing, improving or treating diseases caused by lipofuscin deposition.

The invention relates to a crystalline polymorphic form I, II and III of marimastat, a mixture of the crystalline polymorphic form I and III of marimastat, an amorphous form of marimastat, and processes for their preparation. The invention further relates to a pharmaceutical composition comprising the crystalline polymorphic form I, II or III of marimastat, the mixture of the crystalline polymorphic form I and III of marimastat, the amorphous form of marimastat or a mixture thereof. The invention also relates to the pharmaceutical composition for use as a medicament, and for use in the prevention and treatment of diseases associated with hyperactivity of extracellular matrix metalloproteinases. The invention further relates to the crystalline polymorphic form I, II or III of marimastat, the mixture of the crystalline polymorphic form I and III of marimastat, the amorphous form of marimastat or a mixture thereof for use as a medicament, and for use in the prevention and treatment of diseases associated with hyperactivity of extracellular matrix metalloproteinases.

The invention relates to anti-aging and white flower increasing gum peptide powder as well as a composition and a preparation method of the anti-aging and white flower increasing gum peptide powder. The fish maw peptide powder comprises 85-90 wt% of polypeptide and the balance of water, ash and inevitable impurities. Wherein polypeptides with the molecular weight smaller than 600 Daltons account for 95% or above of all polypeptides, the content of tripeptides is higher than 55%, and the total content of chain elements and isochain elements is not lower than 0.20%. The fish maw peptide powder has the effects of inhibiting excessive free radicals, inhibiting tyrosinase activity, reducing generation of B16 cell melanin, inhibiting matrix metalloproteinase, inhibiting too high activity of elastase and promoting collagen secretion.

This disclosure relates to the field of anticancer drug technology, and discloses a 7-azaindole compound, its synthesis method, and its uses. The structure of the 7-azaindole compound is as follows: This 7-azaindole compound can be used as a fluorescent polarization probe or a degradation chemical probe targeting CSN5; wherein, the fluorescent polarization chemical probe has a good binding affinity to the metalloproteinase CSN5, laying an important foundation for the discovery of novel CSN5 inhibitors; at the same time, the degradation chemical probe exhibits good enzyme-level activity and cell-inhibitory activity, and has the potential to degrade CSN5 protein and its variants, providing a material basis for the development of related drugs targeting CSN5 and the study of its biological functions, and also has great potential in the discovery of cancer immunotherapy drugs and the treatment of other related diseases.